Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP), a biopharmaceutical development company, is focused on acquiring and developing innovative products designed to treat a variety of human diseases. Currently, the company is developing a portfolio of metabolically inert antifolate compounds engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders. Chelsea Therapeutics purposes to create value by building a world-class team, accelerating the development of its product candidates and expanding its therapeutic pipeline. For further information, visit the Company’s web site at www.chelseatherapeutics.com.
- 17 years ago
QualityStocks
Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Narrows Q2 Loss 66% as E-Commerce Growth Offsets Healthcare Headwinds
NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company in healthcare and technology,…
-
QualityStocksNewsBreaks – Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Stands Distinct Against Walker Lane Backdrop
Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) is positioned as investors view the Walker Lane corridor in…
-
QualityStocksNewsBreaks – Solowin Holdings (NASDAQ: SWIN) Targets $1 Billion AUM for Tokenized USD Money Market Product by Year-End 2025
Solowin (NASDAQ: SWIN), a financial services firm bridging traditional and digital assets, announced an initiative…